Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITK-1 Phase 3 Double-blind Placebo-controlled Trial in Temozolomide-resistant Glioblastoma (HLA-A24 Positive)
jRCT2080221684Phase 3Completed
- Sponsor
- Kurume University
- Start
- Dec 2011
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing ITK-1 with Placebo (2 arms). Started Dec 2011; status: completed.
02
Drugs
ITK-1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2080221684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221684.